Originally published by Robert Kraft.
CBS News reports that “a group of state attorneys general nationwide are discussing new ways they can pursue legal action against opioid manufacturers like Purdue Pharma,” the maker of Oxycontin. CBS says that “the latest entity to sue Purdue Pharma for the epidemic is Suffolk County, New York, which filed their lawsuit Wednesday claiming Purdue Pharma and other manufacturers are misleading the public and doctors about the dangers of painkillers.” Meanwhile, “the company says in response to the epidemic they developed alternatives to Oxycontin that are more difficult to abuse, trained law enforcement to address abuses, raised public awareness and set up a prescription drug monitoring system.”
New York county sues Johnson & Johnson for marketing opioid pain medication. In continuing coverage, STAT reports that Suffolk County, New York has filed a lawsuit against drug companies that market opioid pain medications, including Purdue Pharma, Johnson & Johnson, and Endo International. The lawsuit accuses the companies of “using deceptive marketing to downplay the risks” of their medications and of “improperly encouraging physicians to prescribe the medicines in a way that caused some patients to become addicts.” Suffolk County “alleged it paid for prescriptions for its employee health plan inappropriately.”
Number of Americans hospitalized with heart infections caused by injected opioid drugs is increasing, study indicates. HealthDay reports that research indicates “the number of Americans hospitalized with heart infections caused by use of injected opioid drugs is” increasing. Investigators found that “in 2013, 12 percent of hospitalizations for infective endocarditis were related to injection drug use, compared to 7 percent in 2000.” The findings were published in Open Forum Infectious Diseases.
From the news release of the American Association for Justice.
Curated by Texas Bar Today. Follow us on Twitter @texasbartoday.
from Texas Bar Today http://ift.tt/2rvLvcO
via Abogado Aly Website
No comments:
Post a Comment